Title |
Suppression of HBV by Tenofovir in HBV/HIV Coinfected Patients: A Systematic Review and Meta-Analysis
|
---|---|
Published in |
PLOS ONE, July 2013
|
DOI | 10.1371/journal.pone.0068152 |
Pubmed ID | |
Authors |
Huw Price, David Dunn, Deenan Pillay, Firouze Bani-Sadr, Theodora de Vries-Sluijs, Mamta K. Jain, Noriyoshi Kuzushita, Stefan Mauss, Marina Núñez, Reto Nüesch, Marion Peters, Thomas Reiberger, Christoph Stephan, Lionel Tan, Richard Gilson |
Abstract |
Hepatitis B coinfection is common in HIV-positive individuals and as antiretroviral therapy has made death due to AIDS less common, hepatitis has become increasingly important. Several drugs are available to treat hepatitis B. The most potent and the one with the lowest risk of resistance appears to be tenofovir (TDF). However there are several questions that remain unanswered regarding the use of TDF, including the proportion of patients that achieves suppression of HBV viral load and over what time, whether suppression is durable and whether prior treatment with other HBV-active drugs such as lamivudine, compromises the efficacy of TDF due to possible selection of resistant HBV strains. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Japan | 1 | 50% |
United States | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 1% |
France | 1 | 1% |
Brazil | 1 | 1% |
Unknown | 82 | 96% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 22 | 26% |
Student > Master | 14 | 16% |
Student > Bachelor | 8 | 9% |
Other | 6 | 7% |
Student > Ph. D. Student | 6 | 7% |
Other | 16 | 19% |
Unknown | 13 | 15% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 41 | 48% |
Nursing and Health Professions | 5 | 6% |
Immunology and Microbiology | 4 | 5% |
Agricultural and Biological Sciences | 3 | 4% |
Sports and Recreations | 3 | 4% |
Other | 12 | 14% |
Unknown | 17 | 20% |